| 49.91 -0.55 (-1.09%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 65.14  |
1-year : | 69.7 |
| Resists | First : | 55.77 |
Second : | 59.68 |
| Pivot price | 53.7 |
|||
| Supports | First : | 49.45 |
Second : | 41.15 |
| MAs | MA(5) : | 52.28 |
MA(20) : | 53.02 |
| MA(100) : | 49.87 |
MA(250) : | 42.16 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 28.1 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 59.68 | Low : | 29.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SUPN ] has closed below the lower bollinger band by 0.4%. Bollinger Bands are 9.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 51.89 - 52.25 | 52.25 - 52.53 |
| Low: | 48.68 - 49.16 | 49.16 - 49.54 |
| Close: | 49.24 - 49.9 | 49.9 - 50.4 |
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Sat, 14 Mar 2026
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Wed, 11 Mar 2026
SUPN: Four key products drive strong growth and set up a robust outlook for 2026 and beyond - TradingView
Wed, 11 Mar 2026
Dimensional Fund Advisors LP Lowers Holdings in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Tue, 10 Mar 2026
Precision Trading with Supernus Pharmaceuticals Inc. (SUPN) Risk Zones - Stock Traders Daily
Mon, 09 Mar 2026
Insider Selling Alert: Georges Gemayel Sells Shares of Supernus Pharmaceuticals Inc (SUPN) - GuruFocus
Sat, 07 Mar 2026
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Q4 Results And 2026 Guidance Update - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 57 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 103.3 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 4,120 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 18.47 |
| Profit Margin | -5.4 % |
| Operating Margin | -28.9 % |
| Return on Assets (ttm) | -2.1 % |
| Return on Equity (ttm) | -3.7 % |
| Qtrly Rev. Growth | 21.5 % |
| Gross Profit (p.s.) | 11.21 |
| Sales Per Share | 12.51 |
| EBITDA (p.s.) | 0.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 47 (M) |
| Levered Free Cash Flow | 56 (M) |
| PE Ratio | -73.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.7 |
| Price to Sales | 3.98 |
| Price to Cash Flow | 60.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|